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 Isocarbacyclin, a synthetic form of prostacyclin, has been recognized as a 
potential neuroprotective drug which could be used for patients of ischaemic stroke. The 
first goal described in this thesis was to create a new set of analogs of isocarbacyclin 
which had a saturated ring system and perform biological testing on these compounds 
using conditions that mimicked ischaemic stroke symptoms. The synthesis of these 
compounds was to contain three transition metal catalyzed steps which installed a great 
deal of complexity into the molecule in only a few steps. These three steps included a 
palladium catalyzed decarboxylation, a rhodium catalyzed cycloaddition, and a 
ruthenium catalyzed cross metathesis. However, when the first of these three steps, a 
decarboxylation, failed to yield product, efforts went to the discovery of the mechanism 
of this reaction. A second generation synthesis was then conceived, which also contained 
the same three transition metal catalyzed steps, but the decarboxylation step again failed 
to yield sufficient product. Due to the complications discovered with transition metal 
catalyzed decarboxylation reactions, the final investigations described include the results 
of experiments which give light to the necessary elements for decarboxylation to occur.   
Herein is presented the efforts of the total synthesis of isocarbacyclin analogs along with 
the results of explorations into palladium catalyzed decarboxylations.  
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CHAPTER I 
 
ISOCARBACYCLIN AND ANALOGS 
 
 
Background 
Prostacyclin (1, Figure 1) is known as the gold standard for vasodilation (or the 
enlargement of blood vessels) and also causes platelet aggregation.
1
 It is commonly 
prescribed under the names of Flolan or Epoprostenol for patients dealing with high 
blood pressure.
2
 Prostacyclin was discovered by the research group of John Vane, a 
biochemist in the United Kingdom, who went on to win the Nobel Prize in 1982 for his 
work with prostaglandins.
3
 
 
 
Figure 1. Prostacyclin  
 
 
Biologically, prostacyclin is a member of the prostaglandin eicosanoid family and 
is classified as a lipid.
4
 The biological synthesis of prostacyclin begins with arachidonic 
acid and proceeds via three enzymes (Figure 2).
5
 Arachidonic acid (2) is first oxygenated 
by a cyclooxygenase to form an endo-peroxide, PGG2 (3). A peroxidase then cleaves the 
terminal peroide thereby reducing the molecule from PGH2 (4). Finally, prostacyclin
2 
 
synthase cyclizes the molecule and the result is prostacyclin, or PGI2. Other compounds 
made by a similar pathway from arachidonic acid include the prostaglandins PGF2α (5), 
PGE2 (6), and PGD2 (7, Figure 3).
5
  
 
 
Figure 2. The biosynthesis of prostacyclin from arachidonic acid 
 
 
3 
 
 
Figure 3. The structures of PGF2α, PGE2, and PGD2 
 
 
Biological Activity of Prostacyclin and Analogs 
While prostacyclin is highly effective and useful as a vasodilating compound, it is 
also inherently unstable due to the vinyl ether found in the bicyclic ring system which is 
reactive with the carboxylic acid. With a half-life of 3 minutes in vivo
6
, chemists and 
biochemists were inspired to develop and test new analogs of prostacyclin. The first 
generation of analogs simply replaced the ethereal oxygen with a methylene group and 
made no changes to the side chains of the molecule. This compound, known as 
carbacyclin (8, Figure 4), was thought to perform in the same way as prostacyclin 
however, during clinical trials, significant side effects such as headache and severe facial 
flushing were noticed.
7
 These observations led to the development of iloprost (9) which 
removed the alkyl side chain of carbacyclin and replaced it with an alkyne. Iloprost is 
currently on the market as Ventavis and can be inhaled to achieve maximum potency.
8
  
4 
 
 
Figure 4. Structures of prostacyclin, carbacyclin, and iloprost 
 
 
The next logical step in formation of analogs was to isomerize the exo-alkene which led 
to the development of the compounds isocarbacyclin (10, Figure 5) and clinprost (11). 
Clinprost is believed to have slightly better biological activity than isocarbacyclin since 
the methyl ester form is able to cross the blood brain barrier. Enzyme esterases are then 
able to cleave the methyl moiety resulting in the active isocarbacyclin molecule.
9
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Figure 5. Structures of isocarbacyclin, clinprost, 15-deoxy-TIC, and 15-R-TIC 
 
 
As research continued, scientists endeavored to understand the importance of the 
alcohol containing ω-side chain of isocarbacyclin. The compounds 15-deoxy-
tetranorisocarbacyclin (TIC) (12, Figure 5) and 15-R-TIC (13) were designed to test the 
necessity of the alcohol functional group as well as the need for stereochemistry in that 
position.
10
 It was found that when the alcohol stereochemistry was reversed or 
completely removed the activity of the compound changed drastically. While removing 
or reversing the stereochemistry of the alcohol had little effect on the neuroprotective 
nature of the compounds, it almost completely diminished the vasodilating effect.
10
  
As previously stated, the vasodilating capabilities of prostacyclin have been well 
known for decades. While this is helpful to patients with high blood pressure, it was also 
hypothesized to be helpful to victims of ischaemic stoke. There are two types of stroke, 
hemorrhagic and ischaemic. Hemorrhagic strokes occur when blood vessels in the brain 
are weakend and burst causing bleeding on the brain.
11
 Ischaemic strokes, however, are 
6 
 
caused by blood clots in the brain and account for the majority of strokes.
11
 Through the 
opening of the blood vessels in the brain, it was believed that prostacyclin and its analogs 
could help alleviate the neuronal damage caused by ischaemic strokes.  
It was already known that prostacyclin and several of its analogs bind to G-
protein coupled receptors known as PGI2 receptors.
12
 Takechi and co-workers published 
in 1996 that subtle differences in structure caused the molecules to have lower affinity 
when binding to the known PGI2 receptors of the peripheral nervous system and to have 
higher affinity with a novel receptor of the central nervous system. The novel receptor 
was found to be present in the rostral regions of the brain which include the 
hippocampus, cerebral cortex, thalamus, striatum, and septum.
12
 Multiple tests on a 
variety of animals including rats,
13
 rhesus monkeys,
14
 and gerbils
15
 show that this 
receptor is common across multiple species.  
Since it had been discovered that isocarbacyclin has the potential for 
neuroprotection, multiple tests have been designed to test its efficacy. These tests mostly 
include placing neural cells in stressful conditions and dosing with different amounts of 
compound to deduce how well the compound protects the cells. Two methods of stressing 
the cells include exposing them to a high oxygen atmosphere or dosing them with 
xanthine and xanthine oxidase.
10
 Both of these methods cause the mitochondria of cells to 
release of reactive oxygen species (such as oxygen ions or peroxides) which in turn 
damage the neural cells.
16
 During stroke it is most often not the oxygen deprivation that 
degenerates the cells, but a process known as reperfusion, which is the rapid influx of 
7 
 
reactive oxygen species after circulation is restored.
17
 Also, since isocarbacyclin and 
other analogs have shown potent neuroprotective activity it can be reasoned that they 
may also have effect against neurodegenerative diseases such as Alzheimer’s, 
Huntington’s, and Parkinson’s. It is therefore reasonable to conceive that isocarbacyclin 
or closely related analogs could enter the pharmaceutical field as aids against 
neurodegenerative diseases.  
Synthesis of Clinprost 
It is commonly the goal in organic synthesis, especially where medicinal or 
biologically active compounds are concerned, not only to create new or existing 
compounds, but to synthesize them in the fewest number of steps possible. Also, if 
diversification of key components is installed in the last steps then the overall synthesis is 
much more attractive. With both of these concepts in mind Dr. Mitchell Croatt conceived 
a retrosynthesis (Figure 6) of the methyl ester of isocarbacyclin known as clinprost (11) 
and the complete synthesis has been published in Organic Letters.
18
 A look at previous 
synthetic routes shows that many of them contained over twenty steps and allowed for 
very little diversification of the key ω-side chain. This conceived synthesis, having only 
nine steps, beat the shortest previous synthesis by six steps.  
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Figure 6. Retrosynthesis of clinprost 
 
 
Retrosynthetic design began with the installation of the ω-side chain via cross 
metathesis so that diversity could be installed from a single compound (14) in the final 
step. From there the molecule was deconstructed to a tetraene (15) which could undergo a 
[2+2+1] reaction catalyzed by a Rh
I
 catalyst. This tetraene, which appeared simple at 
first, proved to be a difficult molecule to synthesize due to the methylene interrupting 
conjugation of all four double bonds. With little hope for success, a Tsuji-Trost type 
decarboxylation of diester 16 was attempted and the result was a surprisingly high yield 
of tetraene 15.  
The rhodium catalyzed cycloaddition is a step in which three important 
stereocenters are set and reduction using sodium borohydride sets the last stereocenter. 
The method through which this reaction proceeds (Figure 7) is quite elegant.  
9 
 
 
Figure 7. Rhodium catalyzed [2+2+1] cycloaddition 
 
 
When the rhodium catalyst comes into contact with the tetraene it coordinates to 
the conjugated system and forms the first ring of the bicycle as seen by compound 18. 
The rhodium then inserts one of its carbonyl ligands into the second ring thereby 
expanding it by one carbon. Finally, reductive elimination occurs and the reduced 
rhodium species is released from the compound. The carbon monoxide atmosphere that 
the reaction is kept under allows coordination of another carbonyl ligand and the rhodium 
catalyst is then ready to reenter the catalytic cycle.  
The rhodium catalyzed cycloaddition, in addition to a palladium catalyzed 
decarboxylation and ruthenium catalyzed cross-metathesis, make up the final steps of the 
synthesis. These three transition metal catalyzed steps install a large degree of complexity 
from a relatively simple molecule. The synthesis of clinprost that has just been described 
(Figure 8) begins with pimelic acid (21) which undergoes a mono-esterification with 
divinyl carbinol followed by an aldol condensation with acrolein, methylation with 
diazomethane, and finally dehydration with mesyl chloride.  
 
10 
 
 
Figure 8. Synthesis of clinprost 
 
 
The resulting ester (16) is then subjected to Pd
0
 which results in simultaneous 
decarboxylation of the allyl ester and allylic rearrangement to form tetraene 15. This 
compound is then reacted with a Rh
I
 catalyst followed by an in situ reduction; the four 
stereocenters of bicycle 14 are set in this process. Finally, various terminal alkenes can be 
installed using Grubbs-Hoveyda cross metathesis to form the final product (11). The 
concept of using cross metathesis to install diversity in the latter stages of synthesis has 
been used before and has been shown to have excellent yields.
19
  
First Generation Synthesis of Analogs 
It was thought that a new type of analog which does not contain the cyclic alkene 
could be synthesized in almost exactly the same manner. Instead of the mono-esterified 
pimelic acid undergoing the aldol reaction with acrolein, an allyl group could be installed 
via a simple enolate reaction. Then the methylation, decarboxylation, cycloaddition, and 
11 
 
cross-metathesis steps could be performed in the same manner as before with the result 
being a more saturated analog (Figure 9).  
 
 
Figure 9. Proposed synthesis of saturated analog 25 
 
 
Since an alkyl group in the alpha position did not appear to be very different 
chemically or electronically from the alkene it was believed that the palladium catalyzed 
decarboxylation would be as successful as the previous example. Interestingly, when 
saturated diester 22 was subjected to the same decarboxylation conditions as those 
published for the synthesis of clinprost, the expected product was not observed. This 
result gave further evidence to the uniqueness of the previously described 
decarboxylation that will be discussed in greater detail in Chapter III.  
 
 
 
12 
 
Results and Discussion 
The mono-esterification of pimelic acid (21) is a relatively simple reaction that 
proceeds through the well-known coupling mechanism using dicyclohexyl carbodiimide 
(DCC). The DCC, when combined with dimethyl amino pyridine (DMAP), facilitates an 
esterification reaction between carboxylic acids and alcohols. The reaction resulted in 
high yields so long as the DCC solution was added in a dropwise fashion so as to prevent 
di-esterification of the pimelic acid. 
Addition of the allyl group to the alpha position of the ester also proved to be 
relatively facile. At least two equivalents of a strong base (LiHMDS) were used to 
deprotonate the carboxylic acid as well as the most acidic α-proton which formed an 
enolate. This enolate was then able to react with the allyl bromide forming the desired 
product.  
Methylation using trimethylsilyl diazomethane in methanol resulted in 
exceedingly high yields of the necessary diester 22. This compound was then subjected to 
the same decarboxylation conditions that had been used previously in the synthesis of 
clinprost (Figure 10).  
13 
 
 
Figure 10. Decarboxylation of substrate 13 
 
 
Diester 22 was weighed out in 40 mg quantities and added to microwave flasks 
containing a stir bar. Dichloromethane was added as the solvent and palladium tetrakis 
triphenylphosphine was used as the palladium catalyst. After one hour in the microwave 
at 50 °C the reaction was checked by thin layer chromatography. Since no product was 
observed it was resubjected to microwave conditions but at a higher temperature (70 °C). 
After three hours at these conditions there was still no formation of desired product (23). 
The mixture was purified via column chromatography and the purified compounds were 
analyzed using NMR spectroscopy. The results showed that the bis-allylic portion of the 
starting material had rearranged into the linear form but that no decarboxylation had 
occurred (26). Multiple trials were conducted (Table 1) and all yielded the same result; 
the starting material isomerized but did not undergo decarboxylation. 
 
14 
 
Table 1. Decarboxylation conditions attempted with substrate 22 
 
Entry Time Temperature Result 
1 1 hour 50 °C Rearrangement 
2 Overnight Room Temperature Rearrangement 
3 1 hour 70 °C Rearrangement 
4 3 hours 50 °C Rearrangement 
 
 
Since it was perplexing that a vinyl group alpha to the carbonyl would enable 
decarboxylation more efficiently than an alkyl group, the direction of this project 
switched from a total synthesis to an investigation of the method through which the 
decarboxylation reaction proceeded. Although this research did not lead to the total 
synthesis of a biologically active compound as originally planned, the reactions, 
techniques, and strategies were used to create a second generation synthesis which is 
described in Chapter II. Also, the information that came from the decarboxylation efforts 
helped determine the value of the novel decarboxylation from the synthesis of clinprost 
(Chapter III).  
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CHAPTER II 
 
SECOND GENERATION SYNTHESIS 
 
 
Background 
 The synthesis of natural product analogs has many benefits. Often times it is 
possible to make minor changes to the structure of a biologically active compound and 
exponentially increase the activity or make the drug more  marketable. Prostacyclin, the 
gold standard for vasodilation, shows excellent activity, but due to its reactivity and short 
half-life researchers sought out analogs that would be more stable compounds. This is 
how compounds such as iloprost, carbacyclin, isocarbacyclin, and clinprost were 
created.
1
  
 As certain changes were made to the structure of prostacyclin scientists began to 
notice that the drug lost its efficacy for vasodilation but showed high activity for 
neuroprotection.
2
 These changes, correlating with the presence and stereochemistry of the 
alcohol on the ω-side chain, have helped direct researchers to a new goal, 
neuroprotection.
3
 While it is known that prostacyclin binds to a G-protein coupled 
receptor which is contained in the peripheral nervous system,  the new analogs appear to 
bind to a novel receptor associated with the central nervous system.
4
  
 Multiple analogs have been created of isocarbacyclin but the majority of them 
revolve around changes to the ω-side chain. To date, no syntheses are known that contain 
18 
 
a saturated bicyclic ring system. The synthesis described in Chapter I was designed to 
create analogs of this nature and send them for biological testing. However, since the 
synthesis failed to get past the decarboxylation barrier, analogs were never synthesized. It 
was at this point that a new synthesis was conceived involving a compound that 
contained the anion stabilizing group necessary for decarboxylation (Figure 11).   
 
 
Figure 11. Second generation synthesis of saturated analogs 
 
 
Results and Discussion 
 This second generation synthesis begins with commercially available dimethyl 
allyl malonate (27) which undergoes mono-saponification with sodium hydroxide to yield 
mono-acid 28. The carboxylic acid of 28 is then coupled with divinyl carbinol to yield 
diester 29. From this diester the synthesis mimics that of clinprost
5
 and the first 
generation synthesis of a saturated analog as described in Chapter I.  
19 
 
 The first step of the second generation synthesis is a mono-saponification with 
sodium hydroxide (Figure 12). After multiple attempts, it was noticed that a significant 
amount of THF was required in order to solubilize the compound in the aqueous base. 
Even with this knowledge, the products of the reaction always contained unreacted 
starting material, the desired mono-acid, and di-acid which had both methyl groups 
removed. Conveniently, the unreacted starting material was retrieved during purification 
and could be reused.  
 
 
Figure 12. Mono-saponification of dimethyl allylmalonate 
 
 
 Following saponification, the compound was coupled with divinyl carbinol to 
form diester 29 (Figure 13). Ideal conditions for this reaction were found to be when 2 
equivalents of dicyclohexyl carbodiimide were used along with 1.2 equivalents of divinyl 
carbinol.  
 
 
Figure 13. Coupling of methyl malonate and divinyl carbinol 
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 With ester 29 in hand, decarboxylation with concomitant allylic transposition was 
attempted (Figure 14). Despite the presence of an anion-stabilizing group, the 
decarboxylation of diester 29 failed to produce significant amounts of product (30), with 
the major isolated compound being the rearranged product (34). The details of these trials 
are covered extensively in Chapter III.  
 
 
Figure 14. Decarboxylation of diester 27 
 
 
A sufficient amount of ester 30 was produced to proceed to the rhodium catalyzed 
cycloaddition (Figure 15), although it could only be run on a test scale (< 5 mg). With 
only 3 mg of triene 30 we were able to observe the cycloaddition but the product was not 
able to be purified. Also, the final stereocenter of the alcohol was not able to be set 
because the sodium borohydride reaction was not attempted. The final product of the 
rhodium catalyzed cycloaddition is compound 35. Fortunately, future endeavors to create 
saturated isocarbacyclin analogs should be able to have good results with the 
cycloaddition from triene 30 based on the preliminary results obtained along with the 
results of previous published rhodium catalyzed cycloaddition reactions.
6
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Figure 15. Rhodium catalyzed cycloaddition of triene 28 
 
 
 With the unexpected low reactivity for the decarboxylation trials of diester 27, it 
was determined that the final efforts for this thesis should be to investigate 
decarboxylations of anion stabilized bis-allylic systems. The results of these efforts are 
contained in Chapter III.  
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CHAPTER III 
 
DECARBOXYLATION 
 
 
Background 
 Reactions involving the loss of carbon dioxide or “decarboxylation reactions” are 
well known in the realms of organic chemistry and biochemistry. Decarboxylations 
happen frequently inside living systems and the class of reactions is one of the oldest 
known in the organic repertoire.
1
 When most students think of decarboxylation reactions, 
they envision a carboxylic acid decomposing and giving off carbon dioxide while a new 
carbon-hydrogen bond is formed. While these reactions can be useful, they are extremely 
limited when it comes to desired products and usually require harsh conditions such as 
pyrolysis.
2
  
  Decarboxylative coupling is a decarboxylation reaction that closely resembles 
other known cross coupling reactions (Figure 16). In these types of reactions metals, such 
as silver or copper, are used to facilitate decarboxylative carbometalation which is 
necessary before the cross coupling can occur.
3
 Often times the metalated species are 
protonated before the desired carbon-carbon or carbon-heteroatom bond can be formed 
which drastically reduces the yield of the desired product.
4
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Figure 16. Decarboxylative coupling example 
 
 
Recent advances have shown that organometallic catalysts are capable of assisting 
in the decarboxylation of molecules much more complex than simple carboxylic acids.
2
 
A Tsuji-Trost type decarboxylation (Figure 17) utilizes esters that have an anion 
stabilizing group that can stabilize the alpha carbon.
5, 6
 The reaction proceeds as the Pd
0
 
catalyst coordinates to the double bond and cleaves the oxygen-carbon bond. The carbon 
dioxide is then free to leave the system and finally a new carbon-carbon bond is formed 
through a process called decarboxylative allylation.
7
  
 
 
Figure 17. Tsuji-Trost decarboxylation example 
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 The conditions that are required for this type of decarboxylation often include 
high temperatures or the presence of a strong acid in order to force the extrusion of the 
carbon dioxide.
8
 While helpful for decarboxylation, often times these extreme conditions 
will result in the degradation of the compound and little desired product will be formed.  
Dr. Jon Tunge at the University of Kansas has compiled a review of recent 
decarboxylation advances that resemble the Tsuji-Trost model.
9 
While the review covers 
a broad range of substrates, conditions, and catalysts the common thread through all of 
the reactions is that the starting compound is either a malonate, carbonate, or ketoester. 
This is to say that all of the compounds form a stable anion which facilitates the extrusion 
of carbon dioxide.  
Results and Discussion 
In the decarboxylation reaction used for the synthesis of clinprost discussed in 
Chapter I, it is obvious that there is no anion stabilizer present (Figure 18).
10
 It was 
therefore assumed that any substrate that contained the bis-allylic system would 
decarboxylate in the same manner and yield the desired product (Figure 19). As can be 
seen in Table 2, multiple conditions were attempted but the only product observed was 
the rearrangement of the bis-allylic system.  
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Figure 18. Decarboxylation reaction from the synthesis of clinprost 
 
 
 
Figure 19. Decarboxylation attempts with ester 22 
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Table 2. Conditions for decarboxylation attempts with substrate 22 
 
Entry Time Temperature Result 
1 1 hour 50 °C Rearrangement 
2 Overnight Room Temperature Rearrangement 
3 1 hour 70 °C Rearrangement 
4 3 hours 50 °C Rearrangement 
 
 
 The next step was to try decarboxylation conditions with a compound that 
resembled the previous substrate but was easier to make. In two steps ester 47 was made 
from succinic anhydride in large quantities (Figure 20).  
 
 
Figure 20. Synthesis of ester 47 from succinic anhydride 
 
 
Decarboxylation conditions similar to those previously attempted with ester 22 
were tried, however the reaction yielded no desired product (Figure 21). It was at this 
point that additives were considered. A variety of additives which are shown in Table 3 
include Lewis and Brønsted acids. Since other decarboxylation reactions require acidic 
conditions in order to force extrusion of the carbon dioxide, it was hypothesized that 
catalytic amounts of Lewis or Brønsted acids would facilitate decarboxylation. 
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Figure 21. Decarboxylation reaction with ester 47 
 
 
Table 3. Conditions for decarboxylation attempts with ester 47 
 
Entry Additive Time Temperature Result 
1 n/a 1 hour/overnight 50 °C/ RT Rearrangement 
2 
Glacial Acetic 
Acid 
1 hour/overnight 50 °C/ RT Rearrangement 
3 BF3∙OEt2 1 hour/overnight 50 °C/ RT Rearrangement 
4 AlCl3 1 hour/overnight 50 °C/ RT Rearrangement 
 
 
 After examining the results from the aforementioned experiments, it was 
determined that the additives were not helping to facilitate decarboxylation and that the 
original vinyl system was more crucial than originally expected. With this in mind it was 
determined that a bis-allylic benzoate ester should resemble the stability that was in the 
original compound since the α-carbon was sp
2
 hybridized and that decarboxylation 
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should easily occur with this molecule (Figure 22). Table 4 shows the many various 
conditions that were attempted. 
 
 
Figure 22. Decarboxylation reaction with benzoate ester 50 
 
 
As can be seen in Table 4, the first attempts were to recreate conditions that had 
already been tried with the previous systems. Deuterated solvents were then used so that 
crude NMR spectra could be obtained without exposing the reactions to air. In an attempt 
to create decarboxylative coupling conditions similar to those discussed at the opening of 
this chapter, salts such as silver oxide and zinc bromide were used only to yield the same 
undesired product. 
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Table 4. Conditions for decarboxylation trials of benzoate ester 50 
 
Entry Additive Solvent Time/ Temperature Results 
1)  DPPE CDCl3 1 hr/50 °C, overnight/ RT Rearranged 
2)  ZnBr
2
 THF 1 hr/50 °C, overnight/ RT Rearranged 
3)  AgO
2
 d8-Toluene 1 hr/70 °C, overnight/ RT Rearranged 
4)  BF
3
∙OEt
2
 CD2Cl2 1 hr/50 °C, overnight/ RT Rearranged 
5)  Glacial 
Acetic Acid 
 
CD2Cl2 1 hr/50 °C, overnight/ RT Rearranged 
6)  n/a Trifluoroethanol 1 hr/50 °C, overnight/ RT Rearranged 
7)  n/a Trifluoroethanol Overnight/ RT Rearranged 
8)  n/a d6-Acetone (wet) 
 
Overnight/ RT Rearranged 
9)  n/a d4-Methanol Overnight/ RT Rearranged 
10)  n/a Glacial Acetic Acid 1 hr/50 °C, overnight/ RT Rearranged 
11)  n/a CD2Cl2 1 hr/50 °C, overnight/ RT Rearranged 
12)  n/a DMSO 1 hr/RT, 10 min/reflux Decomposition 
13)  n/a d8-Toluene 1 hr/100 °C, overnight/ RT Rearranged, 52 
14)  n/a d8-Toluene 1 hr/120 °C, overnight/ RT Rearranged, 52 
15)  n/a d8-Toluene 1 hr/140 °C, overnight/ RT Rearranged, 52 
16)  n/a d8-Toluene 1 hr/180 °C, overnight/ RT Rearranged, 52 
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 Testing with the original system showed that no decarboxylation was apparent 
when chloroform was used; therefore trials with multiple solvents were attempted. When 
inspected via TLC, reactions carried out in toluene showed a promising non-polar 
compound, however when visualized with NMR it quickly became apparent that it was 
not the desired product. A small amount of decarboxylated product seemed to have 
formed in reaction 13-16 but isomerization had occurred resulting in the conjugated 
system ending with a methyl (ester 52).  
 The final compound lacking anion stabilization that was to be tested was a 
cinnamic ester (Figure 23). It was suspected that this compound would decarboxylate and 
reproduce the original results due to the double bond between the ester and phenyl ring.  
 
 
Figure 23. Decarboxylation reaction for cinnamic ester 
 
 
As it turned out, ester 53 proved difficult to make and decarboxylation attempts 
did not yield the product that was expected. Similar to the results seen in entries 13-16 of 
the benzoate system, the compound did show some decarboxylation but any 
decarboxylated product had rearranged to the terminal methyl (55) shown in Figure 6. 
The only condition that was attempted for this compound was leaving it overnight at 
room temperature. 
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With the results of many failed decarboxylation reactions, several conclusions 
were made. It was first determined that a dienoate must be formed in order for 
decarboxylation to occur when an anion stabilizing group was not present.  This gave 
explanation as to why the cinnamate ester failed to decarboxylate as well as the reaction 
from the synthesis of clinprost. Finally, other members of the Croatt group ran 
experiments testing the necessity of the bis-allylic system as opposed to the typical allyl 
system often seen with decarboxylative allylation.
8
 Interestingly, the bis-allylic ester was 
necessary along with the dienoate for decarboxylation to occur.  
As previously stated, the decarboxylation of compounds containing anion 
stabilizing groups is a known reaction. The review written by Jon Tunge
11
 contains 
numerous examples of ketoesters, malonates, and carbonates which readily undergo 
decarboxylation when introduced to catalysts. It was with this knowledge that the second 
generation synthesis of a saturated isocarbacylin analog was derived (discussed in 
Chapter II). Although there was no proof of bis-allyl systems undergoing decarboxylation 
in the literature, there was no reason to believe that the compounds would not proceed 
through the same Tsuji-Trost type mechanism. However, once subjected to the same 
conditions as were described in the literature, the compound yielded only small amounts 
of the desired product (Figure 24).  
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Figure 24. Decarboxylation reaction with malonate ester 29 
  
 
 Since the yields of the decarboxylation reactions were so low, efforts once again 
moved from the total synthesis of isocarbacyclin analogs to the methodology of 
decarboxylation reactions. Other solvents were used such as dimethyl formamide, 
tetrahydrofuran, and toluene but no positive changes were observed in product yield. 
Finally it was hypothesized that the bis-allylic system was too stable to decarboxylate at 
room temperature so higher temperatures were used. Unfortunately, the higher 
temperatures only forced decomposition and no product formation.  
 The final experiment was to test if a diallyl allylmalonate system would 
decarboxylate. According to the literature references, allyl systems decarboxylated with 
high yields. Diallyl allylmalonate was synthesized via a coupling reaction between di-
acid allylmalonate (33) and allyl alcohol and was then subjected to decarboxylation 
conditions (Figure 25).  
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Figure 25. Decarboxylation reaction with diallyl allylmalonate 
 
 
 Although the product was not able to be recovered, crude NMR gave proof that 
decarboxylation was occurring. The triplet which represented the proton between the 
carbonyls was observed to shrink while a pentet developed more upfield. This 
corresponds to the anticipated results as the newly formed carbon-carbon bond is 
identical to the allyl group which was already in place.  
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CHAPTER IV 
 
EXPERIMENTAL 
 
 
General Information 
All anhydrous reactions were performed with dry solvents in oven dried 
glassware under a nitrogen atmosphere.  Unless otherwise noted, all solvents and reagents 
were obtained from commercial sources and used without further purification. 
Chromatographic purification was performed using silica gel (60 Å, 32-63 μm). NMR 
spectra were recorded using a JEOL ECA spectrometer (500 MHz for 
1
H, 125 MHz for 
13
C). Coupling constants, J, are reported in hertz (Hz) and multiplicities are listed as 
singlet (s), doublet (d), triplet (t), quartet (q), doublet of doublets (dd), triplet of triplets 
(tt), multiplet (m), etc. IR data was obtained with a Perkin Elmer FTIR spectrometer with 
ATR sampling accessory with frequencies reported in cm
-1
. High Resolution Mass 
Spectra were acquired on a ThermoFisher Scientific LTQ Orbitrap XL MS system.
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Pimelic acid ester 21a 
 
 
 
 
Figure 26. Pimelic acid ester 21a
1 
 
 
A solution of DCC (2.45 g, 11.9 mmol) in THF (15 mL) was added to a solution 
of pimelic acid (9.54 g, 59.4 mmol), 1,4-pentadien-3-ol (1.16 mL, 11.9 mmol), and 
DMAP (145 mg, 1.19 mmol) in THF (90 mL) slowly via an additional funnel over 3 
hours. After 2 days, the reaction was filtered through Celite and washed with THF. Silica 
gel was added to the concentrated mixture and the solvent was removed after which the 
dry powder was added to a silica gel column. The product was purified (7:3, 
hexanes/EtOAc) to yield acid 21a (2.1 g, 78%) as a colorless oil. 
 
1
H NMR (500 MHz, CDCl3) δ = 11.34 - 11.00 (s, 1H), 5.88 - 5.79 (m, 2H), 5.74 - 5.69 
(m, 1H), 5.34 - 5.21 (m, 4H), 2.36 (t, J = 7.4 Hz, 4H), 1.72 - 1.63 (m, 4H), 1.44 - 1.35 (m, 
2H) ppm. 
13
C NMR (125 MHz, CDCl3) δ = 179.5, 172.4, 135.1 (2C), 117.4 (2C), 74.9, 34.2, 33.7, 
28.4, 24.5, 24.3 ppm. 
HRMS (ESI) C12H18O4Na [M+Na]
+
, calculated: 249.1103, found: 249.1098. 
IR (neat) 2935, 2866, 1732, 1705, 1641, 1170, 925 cm
-1
. 
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Acid with allylic side chain 21b 
 
Figure 27. Acid with allylic side chain 21b
2
 
  
 
A solution of LiHMDS (3.4 mL, 3.39 mmol) in THF (2.5 mL) was made in a 
round bottom flask at -78 °C. Slowly a solution of mono-ester 21a (200 mg, 1.13 mmol) 
in THF (1.2 mL) was added and allowed to react with the base for 15 minutes. The 
solution was then transferred via cannula to another round bottom flask containing allyl 
bromide (1.25mL, 11.3 mmol) in THF (6 mL). The reaction was allowed to progress for 
2 hours before being quenched with saturated aqueous ammonium chloride 
(approximately 2 mL). Extraction using EtOAc was followed with evaporation and then 
purification using flash silica gel chromatography. A mixture of 10% hexanes in ethyl 
acetate was used to elute the product which was then verified to be pure via NMR and 
TLC. Reaction yielded acid 21b, a pale yellow oil, at 53% (159.5 mg, 0.598 mmol). 
 
1
H NMR (500 MHz, CDCl3) δ = 10.91 - 10.15 (s, 1H), 5.88 - 5.79 (m, 2H), 5.78 - 5.68 
(m, 2H), 5.34 - 5.28 (m, 2H), 5.26 - 5.21 (m, 2H), 5.10 - 5.00 (m, 2H), 2.51 - 2.44 (m, 
1H), 2.43 - 2.32 (m, 3H), 2.28 - 2.20 (m, 1H), 1.72 - 1.59 (m, 3H), 1.57 - 1.48 (m, 1H), 
1.41 - 1.31 (m, 2H) ppm. 
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13
C NMR (125 MHz, CDCl3) δ = 179.3, 174.3, 135.2, 135.1 (2C), 117.6, 117.5, 117.0, 
74.9, 45.1, 36.4, 33.7, 31.3, 26.6, 24.4 ppm. 
HRMS (ESI) C15H22NaO4 [M+Na]+, calculated: 289.1416, found: 289.1410. 
Ester with allylic side chain 22 
 
Figure 28. Ester with allylic side chain 22
3
 
 
 
A solution was made in a round bottom flask at 0 °C of acid 21b (50 mg, 0.19 
mmol) and methanol (1.82 mL). Slowly, trimethylsilyl diazomethane (1 mL, 1.82 mmol) 
was added and the solution was left to stir for 10 minutes. Nitrogen bubbles were 
observed in the solution indicating reaction progress. Nitrogen gas was bubbled through 
the solution for 20 minutes in a well-ventilated hood to remove the toxic gases. 
Following immediate evaporation the resulting colorless oil was subjected to a flash silica 
gel chromatography (95:5 hexanes/EtOAc) to yield methyl ester 21b (49.1 mg, 96%). 
Product purity was determined by thin layer chromatography and NMR. 
 
1
H NMR (500 MHz, CDCl3) δ = 5.82 (ddd, J = 6.2, 10.6, 17.0 Hz, 1H), 5.81 (ddd, J = 
6.2, 10.6, 17.0 Hz, 1H), 5.78 - 5.68 (m, 2H), 5.32 - 5.27 (m, 2H), 5.24 - 5.20 (m, 2H), 
5.10 - 4.99 (m, 2H), 3.71 - 3.60 (m, 3H), 2.51 - 2.43 (m, 1H), 2.42 - 2.34 (m, 1H), 2.30 (t, 
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J = 7.4 Hz, 2H), 2.27 - 2.20 (m, 1H), 1.70 - 1.59 (m, 3H), 1.56 - 1.47 (m, 1H), 1.37 - 1.28 
(m, 2H) ppm. 
13
C NMR (125 MHz, CDCl3) δ = 174.3, 174.0, 135.2, 135.1 (2C), 117.5, 117.5, 117.0, 
74.8, 51.5, 45.2, 36.4, 33.8, 31.3, 26.7, 24.7 ppm. 
HRMS (ESI) C16H25O4 [M+H]
+
, calculated: 303.1572, found: 303.1567. 
Malonic mono-acid 28 
 
Figure 29. Malonic mono-acid 28
5
 
 
 
Dimethyl allylmalonate (2 mL, 12.4 mmol) and THF (2 mL) were combined and 
4 M NaOH (9.6 mL) was added dropwise. The solution was left to stir at room 
temperature until the pH reached seven (approximately one hour). The resulting solution 
was then acidified with HCl and extracted three times using ethyl acetate. The product 
was purified by chromatography (9:1, hexanes, EtOAc) to yield acid 28 (1.04 g, 53%) as 
a pale yellow oil. Spectral data was in agreement with previous reports.
6 
 
41 
 
1
H NMR (500 MHz, CDCl3) δ = 5.80 - 5.74 (m, 1H), 5.14 (dd, J = 1.4, 16.9 Hz, 1H), 
5.09 (dd, J = 1.1, 10.3 Hz, 1H), 3.76 (s, 3H), 3.50 (t, J = 7.2 Hz, 1H), 2.69 – 2.65 (m, 2H) 
ppm. 
Malonic ester 29 
 
Figure 30. Malonic ester 29
1
 
 
 
A solution was made of malonic mono-acid 28 (834 mg, 5.27 mmol), DMAP 
(64.7 mg, 0.53 mmol), divinyl carbinol (0.65 mL, 6.32 mmol), and THF (24 mL). A 
solution of DCC (2.17 g, 10.54 mmol) in THF (20 mL) was then added dropwise at the 
rate of about one drop per two seconds. The solution was left to stir overnight while 
solids formed. After one day the reaction was filtered through Celite to get rid of solids. 
The product was purified (7:3, hexanes/EtOAc) to yield malonic ester 29 (908 mg, 77%) 
as a pale yellow oil. 
 
1
H NMR (500 MHz, CDCl3) δ = 5.84 - 5.72 (m, 4H), 5.30 (dd, J = 1.7, 17.2 Hz, 2H), 
5.24 - 5.22 (m, 2H), 5.13 - 5.09 (m, 1H), 5.06 – 5.04 (m, 1H), 3.72 (s, 3H), 3.48 (t, J = 
7.4 Hz, 1H), 2.67 - 2.63 (m, 2H) ppm.  
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13
C NMR (125 MHz, CDCl3) δ = 169.31, 167.82, 134.54 (2C), 133.92, 117.97, 117.84 
(2C), 76.15, 52.54, 51.69, 32.87 ppm. 
Triene 30 
 
Figure 31. Triene 30
7
 
 
 
 A solution was made of malonic ester 29 (42.4 mg, 0.19 mmol), dichloromethane 
(1 mL), and water (2.5 µL, 0.19 mmol). Palladium tetrakis triphenylphosphine (25 mg, 
0.02 mmol) was then added and the reaction was left to stir for 15 hours. The reaction 
changed from a dark orange color to a pale yellow during this time. Purification via silica 
gel chromatography (95:5, hexanes:EtOAc) yielded triene 30 (1 mg, 3%) as a colorless 
oil. Analytically pure spectral data was not obtained due to the low yield. However, 1H 
NMR spectral analysis showed similarities to related structures.
8
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Bicycle 35 
 
Figure 32. Bicycle 35
8
 
 Triene 30 (3 mg, 0.016  mmol) in dichloroethane (2 mL) was added to an oven-
dried test tube. [RhCl(CO)2]2 (0.6 mg, 0.016 mmol) was then added before purging 
thoroughly with CO. A CO filled balloon was used to maintain a constant CO atmosphere 
and the reaction was heated to 80 °C using an oil bath for 4 hours. TLC and crude NMR 
showed evidence of product formation based on related structures.
8
 No product was 
purified. 
Succinate mono-acid 46 
 
Figure 33. Succinate mono-acid 46
1
 
 
 
A solution of divinyl carbinol (0.3 mL, 2.97 mmol) and dimethyl aminopyridine 
(72 mg, 0.59 mmol) was made in dichloromethane (5 mL). Slowly solid succinic 
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anhydride (482 mg, 4.81 mmol) was added and the solution was left to stir at room 
temperature overnight. The resulting mixture was filtered through celite to get rid of get 
rid of solids and then purified via silica gel chromatography (85:15 hexanes/EtOAc) to 
yield mono-acid 46 (726 mg, 3.94 mmol, 82%). The resulting colorless oil was 
determined pure via NMR. 
 
1
H NMR (500 MHz, CDCl3) δ = 11.17 - 9.46 (br. s, 1H), 5.83 (ddd, J = 5.7, 10.3, 16.6 
Hz, 2H), 5.74 - 5.70 (m, 1H), 5.31 (td, Jt = 1.1 Hz, Jd  = 17.2 Hz, 2H), 5.25 (td, Jt = 1.1 
Hz, Jd  = 10.3 Hz, 2H), 2.73 - 2.65 (m, 4H) ppm. 
13
C NMR (125 MHz, CDCl3) δ = 178.3, 171.1, 134.7 (2C), 117.7 (2C), 75.6, 29.0, 29.1 
ppm. 
HRMS (ESI) C9H13O4 [M+H]
+
, calculated: 185.0814, found: 207.0627. 
Succinate di-ester 47 
 
Figure 34. Succinate di-ester 47
3
 
 
 
A solution was made in a round bottom flask at 0 °C of succinate mono-acid 46 
(125 mg, 0.679 mmol) and methanol (6.8 mL). Slowly, trimethylsilyl diazomethane (3.4 
mL, 6.79 mmol) was added and the solution was left to stir for 10 minutes. The solution 
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was then degassed with nitrogen for 20 minutes to rid the flask of toxic gases. Following 
immediate evaporation the resulting colorless oil was subjected to a flash silica gel 
chromatography (95:5 hexanes/EtOAc) to yield succinate diester 47 (128 mg, 0.644 
mmol, 95%). Product purity was determined by thin layer chromatography and NMR. 
 
1
H NMR (500 MHz, CDCl3) δ = 5.81 (ddd, J = 5.7, 10.3, 16.6 Hz, 2H), 5.71 - 5.67 (m, 
1H), 5.28 (td, Jt = 1.1 Hz, Jd  = 17.2 Hz, 2H), 5.21 (td, Jt = 1.1 Hz, Jd  = 10.3 Hz, 2H), 
3.66 (s, 3H), 2.68 - 2.60 (m, 4H) ppm. 
13
C NMR (125 MHz, CDCl3) δ = 172.6, 171.1, 134.8 (2C), 117.4 (2C), 75.3, 51.7, 29.2, 
28.7 ppm. 
HRMS (ESI) C10H15O4 [M+H]
+
, calculated: 199.0970, found: 221.0782. 
Benzoate ester 50 
 
Figure 35. Benzoate ester 50
4
 
 
 
To a precooled solution of divinyl carbinol (1.05 mL, 10.8 mmol), DMAP (132 
mg, 1.08 mmol), and pyridine (1.3 mL, 16.2 mmol) in dichloromethane (32 mL) at 0 °C. 
was slowly added benzoyl chloride (1.5 mL, 12.9 mmol) and the resulting mixture was 
left stirring at 0 °C for 20 minutes. The solution was left to stir at room temperature 
46 
 
overnight. After 24 hours the solution was quenched with a saturated solution of sodium 
bicarbonate (approximately 5 mL) and then extracted with dichloromethane. The organic 
layer was then evaporated and purified via silica gel chromatography (9:1 
hexanes/EtOAc) to yield benzoate 50 (1.92 g, 10.2 mmol, 94%). The spectroscopic data 
for this compound matched reported data.
9
 
 
1
H NMR (500 MHz, CDCl3) δ = 8.09 (dd, J = 1.0, 8.0 Hz, 2H), 7.57 (t, J = 7.4 Hz, 1H), 
7.45 (t, J = 8.0 Hz, 2H), 6.01 - 5.92 (m, 3H), 5.44 - 5.37 (m, 2H), 5.32 - 5.25 (m, 2H) 
ppm. 
13
C NMR (125 MHz, CDCl3) δ = 165.6, 135.2 (2C), 133.1, 130.4, 129.8 (2C), 128.5 
(2C), 117.7 (2C), 75.6 ppm. 
Cinnamate ester 53 
 
Figure 36. Cinnamate ester 53
1
 
 
 
 A solution of DCC (1.74 g, 8.45 mmol) in THF (10 mL) was added to a solution 
of cinnamic acid (1.25 g, 8.45 mmol), 1,4-pentadien-3-ol (0.82 mL, 8.45 mmol), and 
DMAP (206 mg, 1.69 mmol) in THF (90 mL) slowly via an additional funnel over 3 
hours at 0 °C. After 16 hours, the reactionwas filtered through celite and washed with 
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THF. The product was purified by chromatography (95:5, hexanes, EtOAc) to yield acid 
53 (0.83 g, 43%) as a pale yellow oil. 
 
1
H NMR (500 MHz, CDCl3) δ = 7.73 (d, J = 16.0 Hz, 1H), 7.57 - 7.52 (m, 2H), 7.42 - 
7.38 (m, 3H), 6.49 (d, J = 16.0 Hz, 1H), 5.93 (ddd, J = 6.3, 10.3, 16.6 Hz, 2H), 5.88 - 
5.84 (m, 1H), 5.38 (td, Jt = 1.1 Hz, Jd = 17.2 Hz, 2H), 5.28 (td, Jt = 1.1 Hz, Jd = 10.3 Hz, 
2H) ppm. 
13
C NMR (125 MHz, CDCl3) δ = 165.9, 145.1, 135.0 (2C), 134.3, 130.3, 128.9 (2C), 
128.1 (2C), 118.0, 117.5 (2C), 75.1 ppm. 
HRMS (ESI) C14H15O2 [M+H]
+
, calculated: 215.1072, found: 215.10724. 
Malonic di-acid 33 
 
Figure 37. Malonic di-acid 33
5
 
 
 
 Dimethyl allylmalonate (1 mL, 6.2 mmol) in THF (2 mL) was added to 4 M 
NaOH (6.2 mL). The reaction was left to stir for 1 hour before being acidified with HCl 
and extracted using EtOAc. The product was dried and required no purification to yield 
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acid 35 (885 mg, 99%) as a white crystalline solid. The spectroscopic data for this 
compound matched reported data.
10 
 
1
H NMR (500 MHz, CDCl3) δ = 5.83 (m, 1H), 5.20-5.11 (m, 2H), 3.54 (t, J = 7.2 Hz, 
1H), 2.71 – 2.68 (m, 2H) ppm. 
Diallyl allylmalonate 56 
 
Figure 38. Diallyl allylmalonate 56
1
 
 
 
A solution was made of malonic di-acid starting material (371 mg, 2.57 mmol), 
DMAP (31 mg, 0.26 mmol), allyl alcohol  (0.87  mL, 12.9  mmol), and THF 15 mL). A 
solution of DCC (1.59 g, 7.71 mmol) in THF (10 mL) was then added dropwise at the 
rate of about one drop per two seconds. The solution was left to stir overnight while 
solids formed. After one day the reaction was filtered through Celite to get rid of solids. 
The product was purified (95:5, hexanes/EtOAc) to yield diallyl allylmalonate 56 (86 mg, 
14%) as a pale yellow oil. 
 
1
H NMR (500 MHz, CDCl3) δ = 5.89 (ddt, Jd = 5.7, 17 Hz,  Jt = 7.2 Hz, 2H), 5.78 (ddt, 
Jd = 10.3, 17.2 Hz, Jt = 6.9 Hz, 1H), 5.34 - 5.30 (m, 2H), 5.25 – 5.22 (m, 2H), 5.15 – 5.10 
49 
 
(m, 1H), 5.08 – 5.05 (m, 1H), 4.67 – 4.60 (m, 4H), 3.50 (t, J = 7.2), 2.69 – 2.66 (m, 2H) 
ppm.  
13
C NMR (125 MHz, CDCl3) δ = 168.65 (2C), 133.96, 131.60 (2C), 118.81 (2C), 117.93, 
66.07 (2C), 51.62, 32.96 ppm. 
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APPENDIX A 
 
NMR SPECTRA OF COMPOUNDS 
 
 
NMR spectra were recorded using a JEOL ECA spectrometer (500 MHz for 
1
H, 
125 MHz for 
13
C). All spectra were taken at room temperature in deuterated chloroform 
unless otherwise noted. 
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Chemical Shift (ppm)
13
C NMR of 29
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168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32
Chemical Shift (ppm)
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H NMR of 56
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13
C NMR of 56
KG-132-C-2.jdf
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